Overview Dividends

(DOCS) Doximity - Ratings and Ratios

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US26622P1075

Collaboration, Scheduling, Telehealth, Documentation, News

DOCS EPS (Earnings per Share)

EPS Growth (3Y CAGR): -55.56%
EPS Trend (3Y Correlation): 16.1%

DOCS Revenue

Revenue Growth (3Y CAGR): 13.83%
Revenue Trend (3Y Correlation): 85.4%

Description: DOCS Doximity October 31, 2025

Doximity, Inc. (NASDAQ: DOCS) runs a U.S.-focused digital network that equips physicians, nurse practitioners, physician assistants, medical students, pharmaceutical firms, and health systems with tools for professional collaboration, career management, on-call scheduling, documentation, and virtual patient visits.

Key operating metrics (as of the most recent FY 2023 filing) include roughly 2 million active members and a year-over-year revenue growth rate of about 30 %, driven primarily by pharmaceutical advertising and subscription services for clinical workflow tools. The platform’s telehealth adoption surged during the pandemic, and while growth has moderated, the broader health-care-technology sector remains buoyed by ongoing digitization mandates and reimbursement reforms that favor remote care.

Strategic risks to watch are user-engagement retention (especially as competing networks emerge), regulatory scrutiny over data privacy, and the concentration of revenue in pharma advertising, which could be vulnerable to shifts in marketing spend. Conversely, the expanding need for integrated digital documentation and the rising prevalence of value-based care models create tailwinds for Doximity’s suite of workflow solutions.

For a deeper quantitative assessment of Doximity’s valuation metrics, you may find the ValueRay platform’s analyst toolkit useful.

DOCS Stock Overview

Market Cap in USD	12,519m
Sub-Industry	Health Care Technology
IPO / Inception	2021-06-24

DOCS Stock Ratings

Growth Rating	63.9%
Fundamental	84.6%
Dividend Rating	-
Return 12m vs S&P 500	28.3%
Analyst Rating	3.68 of 5

DOCS Dividends

Currently no dividends paid

DOCS Growth Ratios

Growth Correlation 3m	14%
Growth Correlation 12m	59.5%
Growth Correlation 5y	3.5%
CAGR 5y	39.09%
CAGR/Max DD 3y (Calmar Ratio)	0.78
CAGR/Mean DD 3y (Pain Ratio)	1.75
Sharpe Ratio 12m	0.79
Alpha	25.00
Beta	1.377
Volatility	46.36%
Current Volume	1298.9k
Average Volume 20d	1061k
Stop Loss	61.8 (-3.4%)
Signal	-0.38

Piotroski VR‑10 (Strict, 0-10) 5.5

Net Income (235.1m TTM) > 0 and > 6% of Revenue (6% = 35.4m TTM)

FCFTA 0.24 (>2.0%) and ΔFCFTA 8.75pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 148.3% (prev 156.6%; Δ -8.35pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.24 (>3.0%) and CFO 294.1m > Net Income 235.1m (YES >=105%, WARN >=100%)

Net Debt (-125.4m) to EBITDA (259.1m) ratio: -0.48 <= 3.0 (WARN <= 3.5)

Current Ratio 6.47 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (201.2m) change vs 12m ago 0.97% (target <= -2.0% for YES)

Gross Margin 90.14% (prev 89.65%; Δ 0.49pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 51.77% (prev 45.98%; Δ 5.79pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio -9.42 (EBITDA TTM 259.1m / Interest Expense TTM -26.4m) >= 6 (WARN >= 3)

Altman Z'' 7.24

(A) 0.73 = (Total Current Assets 1.03b - Total Current Liabilities 159.9m) / Total Assets 1.20b

(B) 0.10 = Retained Earnings (Balance) 117.1m / Total Assets 1.20b

(D) 0.66 = Book Value of Equity 118.5m / Total Liabilities 178.9m

Total Rating: 7.24 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 84.62

1. Piotroski 5.50pt = 0.50

2. FCF Yield 2.46% = 1.23

3. FCF Margin 48.73% = 7.50

4. Debt/Equity 0.01 = 2.50

5. Debt/Ebitda -0.48 = 2.50

6. ROIC - WACC (= 9.02)% = 11.27

7. RoE 22.94% = 1.91

8. Rev. Trend 85.39% = 6.40

9. EPS Trend 16.08% = 0.80

What is the price of DOCS shares?

As of November 06, 2025, the stock is trading at USD 63.99 with a total of 1,298,854 shares traded.
Over the past week, the price has changed by -4.16%, over one month by -12.04%, over three months by +10.46% and over the past year by +52.58%.

Is Doximity a good stock to buy?

Yes, based on ValueRay´s Fundamental Analyses, Doximity (NYSE:DOCS) is currently (November 2025) a good stock to buy. It has a ValueRay Fundamental Rating of 84.62 and therefor a positive outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of DOCS is around 60.12 USD . This means that DOCS is currently overvalued and has a potential downside of -6.05%.

Is DOCS a buy, sell or hold?

Doximity has received a consensus analysts rating of 3.68. Therefor, it is recommend to hold DOCS.

Strong Buy: 5
Buy: 3
Hold: 11
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the DOCS price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	70.7	10.5%
Analysts Target Price	70.7	10.5%
ValueRay Target Price	68.6	7.2%

DOCS Fundamental Data Overview October 27, 2025

Market Cap USD = 12.52b (12.52b USD * 1.0 USD.USD)
P/E Trailing = 57.1282
P/E Forward = 47.619
P/S = 21.2319
P/B = 13.1472
P/EG = 2.4191
Beta = 1.377
Revenue TTM = 589.6m USD
EBIT TTM = 248.2m USD
EBITDA TTM = 259.1m USD
Long Term Debt = 11.8m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 4.34m USD (from shortTermDebt, last quarter)
Debt = 11.8m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -125.4m USD (from netDebt column, last quarter)
Enterprise Value = 11.69b USD (12.52b + Debt 11.8m - CCE 841.0m)
Interest Coverage Ratio = -9.42 (Ebit TTM 248.2m / Interest Expense TTM -26.4m)
FCF Yield = 2.46% (FCF TTM 287.3m / Enterprise Value 11.69b)
FCF Margin = 48.73% (FCF TTM 287.3m / Revenue TTM 589.6m)
Net Margin = 39.88% (Net Income TTM 235.1m / Revenue TTM 589.6m)
Gross Margin = 90.14% ((Revenue TTM 589.6m - Cost of Revenue TTM 58.1m) / Revenue TTM)
Gross Margin QoQ = 89.18% (prev 89.54%)
Tobins Q-Ratio = 9.71 (Enterprise Value 11.69b / Total Assets 1.20b)
Interest Expense / Debt = 32.73% (Interest Expense 3.88m / Debt 11.8m)
Taxrate = 16.88% (10.8m / 64.1m)
NOPAT = 206.3m (EBIT 248.2m * (1 - 16.88%))
Current Ratio = 6.47 (Total Current Assets 1.03b / Total Current Liabilities 159.9m)
Debt / Equity = 0.01 (Debt 11.8m / totalStockholderEquity, last quarter 1.03b)
Debt / EBITDA = -0.48 (Net Debt -125.4m / EBITDA 259.1m)
Debt / FCF = -0.44 (Net Debt -125.4m / FCF TTM 287.3m)
Total Stockholder Equity = 1.03b (last 4 quarters mean from totalStockholderEquity)
RoA = 19.52% (Net Income 235.1m / Total Assets 1.20b)
RoE = 22.94% (Net Income TTM 235.1m / Total Stockholder Equity 1.03b)
RoCE = 23.93% (EBIT 248.2m / Capital Employed (Equity 1.03b + L.T.Debt 11.8m))
RoIC = 20.12% (NOPAT 206.3m / Invested Capital 1.03b)
WACC = 11.11% (E(12.52b)/V(12.53b) * Re(11.09%) + D(11.8m)/V(12.53b) * Rd(32.73%) * (1-Tc(0.17)))
Discount Rate = 11.09% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 0.17%
[DCF Debug] Terminal Value 72.18% ; FCFE base≈237.3m ; Y1≈292.7m ; Y5≈499.4m
Fair Price DCF = 38.17 (DCF Value 5.21b / Shares Outstanding 136.4m; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: 16.08 | EPS CAGR: -55.56% | SUE: -4.0 | # QB: 0
Revenue Correlation: 85.39 | Revenue CAGR: 13.83% | SUE: 1.22 | # QB: 1

Additional Sources for DOCS Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle